AIDS and Pathogens

John Burnett, Ph.D.
John Burnett, assistant research professor in the Department of Molecular and Cellular Biology, received his Ph.D. from University of California Berkeley. His laboratory focuses on engineering biological therapeutics, such as specialized RNA aptamers for targeted delivery, and genome editing technologies for genetic and infectious diseases.
 
Edouard Cantin, Ph.D.
Edouard Cantin, professor in the Department of Molecular Imaging & Therapy, received his Ph.D. from Cambridge University. His research focuses on defining the mechanism by which herpes simplex virus contributes to encephalitis and keratitis, and dissecting the immunological responses that the host mounts against the virus.
 
Saswati Chatterjee, Ph.D.
Saswati Chatterjee, professor in the Department of Surgery, received her Ph.D. from McGill University, Canada. Her research is directed at using recombinant adeno-associated virus vectors to genetically modify hematopoietic stem cells, with the ultimate goal of treating an array of diseases including HIV and cancer.
 
Don Diamond, Ph.D.
Don Diamond, professor in the Department of Hematology & Hematopoietic Cell Transplantation, received his Ph.D. from Harvard Medical School. His laboratory is focusing on developing a novel approach that uses attenuated salmonella encoding a short hairpin RNA to decrease the expression of molecules contributing to tumor rejection and controlling metastasis.
 
Yuman Fong, M.D. 
Yuman Fong, The Sangiacomo Family Chair in Surgical Oncology, received his M.D. from Cornell University Medical College. His research is currently focusing on developing genetically engineered viruses to effectively target and destroy cancer cells, especially those that are resistant to chemo- and radiation therapies.
 
Markus Kalkum, Ph.D.
Markus Kalkum, professor in the Department of Molecular Imaging & Therapy and director of the Mass Spectrometry & Proteomic Core, received his Ph.D. from Freie Universität Berlin. His laboratory focuses on the development of novel proteomic technology to study pathogenic fungal and bacterial proteomes for vaccine development.
 
Javier Gordon Ogembo, Ph.D.
Javier Gordon Ogembo, assistant professor in the Department of Immuno-Oncology, received his Ph.D. from Nagoya University. He is studying how oncogenic viruses, such as Epstein-Barr virus and human papillomavirus, overcome cellular barriers and escape host immune responses, with the goal of using this knowledge to aid the development of effective vaccines.
 
John Rossi, Ph.D.
John Rossi, chair of the Department of Molecular and Cellular Biology, and the Helen & Morgan Chu Dean's Chair of the Graduate School of Biological Sciences, received his Ph.D. from University of Connecticut. His laboratory focuses on developing RNA aptamers and cell internalizing delivery vehicle for the treatments of HIV infection and cancers.
 
John Zaia, M.D.
John Zaia, director of the Center for Gene Therapy and the Aaron D. Miller and Edith Miller Chair in Gene Therapy, received his M.D. from Harvard Medical School. His team collaborates with City of Hope investigators to test various approaches, including genome editing of the CCR5 gene important for HIV infection, in providing resistance to HIV infection and slowing the progression of AIDS.